American Superconductor Corp. today announced the formation of a new corporate identity, “AMSC.” The company has a new tagline as well: “Smarter, cleaner … better energy.” AMSC’s wind and grid products have also been rebranded as Windtec Solutions and Gridtec Solutions.
Boston, Ma-based AMSC is focused on providing sustainable energy through wind power, while also providing advanced grid systems. In 2011, AMSC will be showcasing products at China WindPower, where it will introduce its Wind-RT system, specifically for integration into existing Chinese squirrel cage induction generators. AMSC will also be exhibiting at Solar Power International 2011, with its SolarTie megawatt-class inverter system for solar power plants.
AMSC’s new strategy for their rebranding is to align business by end market rather than technologies. To that end, WindTec Solutions is gearing to provide advanced wind turbines more quickly and efficiently. Similarly, Gridtec Solutions aims to deploy efficient, reliable power grid solutions that extend from the point of power generation through the process of distribution of generated energy.
AMSC President and Chief Executive Officer, Daniel McGahn, said, “When we were founded nearly 25 years ago, we had operations only in the United States and our sole focus was on superconductors. Today, we have operations throughout North America, Europe and Asia. Meanwhile, our Windtec Solutions and Gridtec Solutions are powering gigawatts of renewable energy globally and enhancing the performance and reliability of power networks in more than a dozen countries. Our evolution from American Superconductor to AMSC better reflects who we are today and supports our continued diversification. The new identity is just one of the changes that we are making to support a more diversified and sustainable company. In recent months, AMSC has taken actions to streamline and strengthen its business. We have created a flatter, leaner organization that is more nimble and flexible to emerging opportunities; aligned our business to better serve the wind and grid markets; and refined our strategic priorities to capitalize on our near- and long-term opportunities.”
McGahn continued, “Each day at AMSC, we are driven by our vision to power the world with better energy. We have aligned our business to focus on our core competencies, and this strategic investment will help us to communicate the new AMSC more clearly and more effectively to our employees and all of our customers worldwide.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, October 17, 2011
Kirin International Holding, Inc. (KIRI) Launches Two Major Projects in China
Kirin International Holding, Inc., the largest private developer of residential mixed-use properties in Xingtai, China, today announced the launch of two major projects, Kirin Bay and No. 79 Courtyard, both of which recently obtained their Presale Permits from the Xingtai Administration Bureau of Real Estate.
The Presale Permits marks a significant step in the company’s efforts to begin and complete the projects as it enables Kirin to contract with buyers.
“Once Kirin obtained the Presale Permits for Kirin Bay and No. 79 Courtyard, the Company officially launched the marketing for these two major projects,” Kirin CEO Longlin Hu stated in the press release. “The Chinese government authorities have become more and more strict on presales management, so only upon the issuance of the presale permit can a real estate company start to sign contacts with potential buyers.”
Kirin estimates between approximately $130 million to $160 million in contract sales for 2011, and between approximately $20 million to $35 million in profit.
“Kirin will take advantage of the best-selling period of October and November to market our projects to the citizens of Xingtai,” Hu stated. “We also believe our financial performance will be positively improved by the on-time issuance of the Presale Permits.”
Kirin Bay land area spans more than 660,000 square meters, and is comprised of mixed-use, residential and commercial properties. Upon completion, Kirin said it expects the project to become the largest high-end residential community in Xingtai. The No. 79 Courtyard Project spans 290,000 square meters, with total building area of approximately 450,000 square meters. The project is designed as a high-end residential development with some mixed commercial use.
Kirin has also started inquiring on property conditions and related land and development approval procedures in Shijiazhuang of Hebei Province and in Dezhou and Tai’an of Shandong Province, and the suburban area of Tianjin, which are all adjacent to the Beijing-to-Shanghai high-speed rail corridor.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Presale Permits marks a significant step in the company’s efforts to begin and complete the projects as it enables Kirin to contract with buyers.
“Once Kirin obtained the Presale Permits for Kirin Bay and No. 79 Courtyard, the Company officially launched the marketing for these two major projects,” Kirin CEO Longlin Hu stated in the press release. “The Chinese government authorities have become more and more strict on presales management, so only upon the issuance of the presale permit can a real estate company start to sign contacts with potential buyers.”
Kirin estimates between approximately $130 million to $160 million in contract sales for 2011, and between approximately $20 million to $35 million in profit.
“Kirin will take advantage of the best-selling period of October and November to market our projects to the citizens of Xingtai,” Hu stated. “We also believe our financial performance will be positively improved by the on-time issuance of the Presale Permits.”
Kirin Bay land area spans more than 660,000 square meters, and is comprised of mixed-use, residential and commercial properties. Upon completion, Kirin said it expects the project to become the largest high-end residential community in Xingtai. The No. 79 Courtyard Project spans 290,000 square meters, with total building area of approximately 450,000 square meters. The project is designed as a high-end residential development with some mixed commercial use.
Kirin has also started inquiring on property conditions and related land and development approval procedures in Shijiazhuang of Hebei Province and in Dezhou and Tai’an of Shandong Province, and the suburban area of Tianjin, which are all adjacent to the Beijing-to-Shanghai high-speed rail corridor.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, October 13, 2011
ULURU Inc. (ULU) Announces Licensing Agreement for Marketing Altrazeal in Europe
ULURU Inc., a Texas based specialty pharmaceutical company, announced today a binding letter of intent with Melmed Holdings AG, a Swiss holding company, to license ULURU’s Altrazeal®, a revolutionary wound treatment technology, for marketing in the European Union. Altrazeal is expected to be launched in Germany during the first quarter of 2012, with expansion to the U.K., France, Spain, and Italy to occur once price reimbursement approval has been received in each market.
Initial marketing will focus on the treatment of diabetic foot ulcers, a growing market throughout Europe. In the U.S., according to the company, only 31% of diabetic foot ulcers are healed in 20 weeks, a condition for which Altrazeal has demonstrated significant clinical advantages. ULURU will receive a licensing payment, plus interest, in the Melmed subsidiary company being formed to market Altrazeal, for a total value of approximately $2.5 million. In addition, ULURU will supply Altrazeal at a price equal to 30% of the European sales price and get royalties on sales within the territory.
ULURU is focused on the development of wound management and oral care products, providing improved clinical outcomes through controlled delivery, utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. The company is committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products. Their stated strategy is to:
• Develop and commercialize a customer focused portfolio of innovative wound care products to treat the various phases of wound healing
• Develop the oral-transmucosal technology and generate revenues through multiple licensing agreements
• Develop the Nanoflex technology for the medical aesthetics market, and enter into one or more strategic partnerships to bring these products to market
Altrazeal Transforming Powder Dressing uses the proprietary Nanoflex technology to promote the healing of exuding wounds. The unique powder particles have been rigorously developed to the exact scale and proportion necessary to provide optimal oxygen and vapor transpiration, microbial impermeability, tensile strength, and flexibility.
For additional information on ULURU, visit the company’s website at www.ULURUInc.com
For further information about Altrazeal, please visit www.Altrazeal.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Initial marketing will focus on the treatment of diabetic foot ulcers, a growing market throughout Europe. In the U.S., according to the company, only 31% of diabetic foot ulcers are healed in 20 weeks, a condition for which Altrazeal has demonstrated significant clinical advantages. ULURU will receive a licensing payment, plus interest, in the Melmed subsidiary company being formed to market Altrazeal, for a total value of approximately $2.5 million. In addition, ULURU will supply Altrazeal at a price equal to 30% of the European sales price and get royalties on sales within the territory.
ULURU is focused on the development of wound management and oral care products, providing improved clinical outcomes through controlled delivery, utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. The company is committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products. Their stated strategy is to:
• Develop and commercialize a customer focused portfolio of innovative wound care products to treat the various phases of wound healing
• Develop the oral-transmucosal technology and generate revenues through multiple licensing agreements
• Develop the Nanoflex technology for the medical aesthetics market, and enter into one or more strategic partnerships to bring these products to market
Altrazeal Transforming Powder Dressing uses the proprietary Nanoflex technology to promote the healing of exuding wounds. The unique powder particles have been rigorously developed to the exact scale and proportion necessary to provide optimal oxygen and vapor transpiration, microbial impermeability, tensile strength, and flexibility.
For additional information on ULURU, visit the company’s website at www.ULURUInc.com
For further information about Altrazeal, please visit www.Altrazeal.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen Therapeutics, Inc. (VSTA) Holds Key Position in Pharmaceutical Marketplace
VistaGen Therapeutics is center stage in one of the most important developments in recent history for the pharmaceutical industry. The California biotechnology company is set to use stem cell technology to transform the way new drug candidates are developed by allowing preclinical drug testing on actual human cells, which is believed to be far more clinically relevant than the current animal testing paradigm.
VistaGen’s revolutionary bioassay system can help pharmaceutical companies avoid spending years and millions of dollars developing and testing a new drug, only to find out in late-phase human tests that the drug is toxic to the heart and has to be discontinued. It’s one of the industry’s biggest fears, largely because it is such a common event. Approximately one third of potential new drugs fail in preclinical or clinical trials due to heart safety issues. It’s a major concern for the rest of us as well, since it significantly slows the development and approval of new drugs.
VistaGen uses advanced stem cell technology to grow specialized mature human cells which can then be used to create novel bioassay systems for superior predictive toxicology. Companies and researchers can learn early on if a drug needs to be modified to reduce heart safety hazards, saving huge amounts of time and money, and giving the drug a solid chance of making it to market. In addition, past candidates that have been shelved for heart toxicity concerns can now be cost effectively re-evaluated in the lab, allowing the development of safer variants.
VistaGen’s “human clinical trials in a test tube” technology gives the company many unique advantages in the marketplace:
• Proprietary differentiation of human pluripotent stem cells into mature cells
• Mature cells available for drug rescue, drug discovery, and cell therapy
• Drug rescue leverages prior investment on shelved drugs
• Opportunity to build a pipeline of drug rescue variants
• Numerous cell therapies, including heart, liver, and cartilage repair
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen’s revolutionary bioassay system can help pharmaceutical companies avoid spending years and millions of dollars developing and testing a new drug, only to find out in late-phase human tests that the drug is toxic to the heart and has to be discontinued. It’s one of the industry’s biggest fears, largely because it is such a common event. Approximately one third of potential new drugs fail in preclinical or clinical trials due to heart safety issues. It’s a major concern for the rest of us as well, since it significantly slows the development and approval of new drugs.
VistaGen uses advanced stem cell technology to grow specialized mature human cells which can then be used to create novel bioassay systems for superior predictive toxicology. Companies and researchers can learn early on if a drug needs to be modified to reduce heart safety hazards, saving huge amounts of time and money, and giving the drug a solid chance of making it to market. In addition, past candidates that have been shelved for heart toxicity concerns can now be cost effectively re-evaluated in the lab, allowing the development of safer variants.
VistaGen’s “human clinical trials in a test tube” technology gives the company many unique advantages in the marketplace:
• Proprietary differentiation of human pluripotent stem cells into mature cells
• Mature cells available for drug rescue, drug discovery, and cell therapy
• Drug rescue leverages prior investment on shelved drugs
• Opportunity to build a pipeline of drug rescue variants
• Numerous cell therapies, including heart, liver, and cartilage repair
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Accelr8 Technology (AXK) in Discussions to Explore Additional Funding
Accelr8 Technology Corp., a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery and bio-detection, today announced that in regards to the end of its technology evaluation agreement with Novartis, it is in discussions to search within Novartis for funding options to complete product development.
“Recent reorganization in the Novartis Vaccines and Diagnostics division has delayed project decisions until the reorganization is completed. But, thanks to Novartis, Accelr8 is on a rapid development path. To maintain momentum we are taking direct action to develop additional paths to finish the product development,” David Howson, Accelr8’s president, stated in the press release.
The talks follow Novartis business analyses and successful Proof of Concept technical studies, which were conducted jointly between the companies. Accelr8’s management confirmed the successful technical studies, and additionally noted that several independent business analyses and advisory boards are in-line with Accelr8’s assessments.
As Accelr8 explores alternative funding, there are no standstill or first-right conditions that prohibit Accelr8 from pursuing alternatives outside of Novartis.
Accelr8 has negotiated with other companies for BACcel™ applications that complement clinical diagnostics, such as pharma development, and said it is opening discussions with clinical diagnostics companies as well.
“At the same time, we are completing formal technical studies that are already underway with Novartis. These include Proof of Concept studies with positive blood cultures containing complex Gram-negative organisms that express broad-spectrum resistance. Our objective is to present the results at the next available international clinical congress. Finally, we expect a corporate update from Novartis before Thanksgiving,” Howson stated.
For more information visit: www.accelr8.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Recent reorganization in the Novartis Vaccines and Diagnostics division has delayed project decisions until the reorganization is completed. But, thanks to Novartis, Accelr8 is on a rapid development path. To maintain momentum we are taking direct action to develop additional paths to finish the product development,” David Howson, Accelr8’s president, stated in the press release.
The talks follow Novartis business analyses and successful Proof of Concept technical studies, which were conducted jointly between the companies. Accelr8’s management confirmed the successful technical studies, and additionally noted that several independent business analyses and advisory boards are in-line with Accelr8’s assessments.
As Accelr8 explores alternative funding, there are no standstill or first-right conditions that prohibit Accelr8 from pursuing alternatives outside of Novartis.
Accelr8 has negotiated with other companies for BACcel™ applications that complement clinical diagnostics, such as pharma development, and said it is opening discussions with clinical diagnostics companies as well.
“At the same time, we are completing formal technical studies that are already underway with Novartis. These include Proof of Concept studies with positive blood cultures containing complex Gram-negative organisms that express broad-spectrum resistance. Our objective is to present the results at the next available international clinical congress. Finally, we expect a corporate update from Novartis before Thanksgiving,” Howson stated.
For more information visit: www.accelr8.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, October 12, 2011
Integrated Device Technology (IDTI) Launches Industry First with Integrated Timing, Thermal Management Solution
Integrated Device Technology Inc., a semiconductor solutions provider, today highlighted its roll-out of the industry’s first integrated timing, thermal sensor and fan control solution targeted at PC mobile platforms, digital video recorders (DVRs), set top boxes (STBs), Network Attached Storage (NAS) and enterprise Ethernet switches and routers.
The company said the technology reduces bill of materials (BOM) and application footprint, saving costs and increasing board space in densely populated enclosures.
“IDT’s new integrated timing and thermal management solution takes a system-level approach to bring value to the application,” Ram Iyer, vice president and general manager of the Computing and Multimedia Division stated in the press release. “We’ve leveraged our timing expertise and combined it with precision analog functions to simplify our customers’ designs, resulting in a space-saving, lower-cost solution that allows our customers to get to market sooner.”
The IDT 9TCS108x devices use a low-power system timing solution integrated with two-channel thermal sensor, and four-wire pulse width modulation (PWM) fan controller on a single chip. Because of its low-power PLL design, battery life is extended in portable applications. The multiple clock outputs of the device can replace on-board crystals to reduce physical size and weight.
The integrated thermal sensor features two channels designed to detect overheating conditions and improve system reliability with precise accuracy. A separate temperature alert function for each channel can be programmed to generate reference data for the fan controller or an alert signal for the system, providing design flexibility for different applications.
In addition, the fan controller allows for direct fan control without requiring a system interrupt or supplementary control circuitry, further simplifying the design. The new family of devices offer a number of output and frequency variants, and also provide additional thermal sensors and other control pins, which allows system designers to choose the device best suited to their application.
For more information visit www.IDT.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company said the technology reduces bill of materials (BOM) and application footprint, saving costs and increasing board space in densely populated enclosures.
“IDT’s new integrated timing and thermal management solution takes a system-level approach to bring value to the application,” Ram Iyer, vice president and general manager of the Computing and Multimedia Division stated in the press release. “We’ve leveraged our timing expertise and combined it with precision analog functions to simplify our customers’ designs, resulting in a space-saving, lower-cost solution that allows our customers to get to market sooner.”
The IDT 9TCS108x devices use a low-power system timing solution integrated with two-channel thermal sensor, and four-wire pulse width modulation (PWM) fan controller on a single chip. Because of its low-power PLL design, battery life is extended in portable applications. The multiple clock outputs of the device can replace on-board crystals to reduce physical size and weight.
The integrated thermal sensor features two channels designed to detect overheating conditions and improve system reliability with precise accuracy. A separate temperature alert function for each channel can be programmed to generate reference data for the fan controller or an alert signal for the system, providing design flexibility for different applications.
In addition, the fan controller allows for direct fan control without requiring a system interrupt or supplementary control circuitry, further simplifying the design. The new family of devices offer a number of output and frequency variants, and also provide additional thermal sensors and other control pins, which allows system designers to choose the device best suited to their application.
For more information visit www.IDT.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
China BCT Pharmacy, Inc. (CNBI) Announces Launch of 11 New Retail Pharmacy Stores in Guangxi
China BCT Pharmacy, Inc., a company that engages in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products in the People’s Republic of China, recently announced that the Company is currently in the final stages of launching eleven new retail pharmacy stores in Guangxi.
The new retail stores are primarily located in Liuzhou City and Liucheng County and are, on average, a size of 67 square meters. The company has estimated that the total upfront capital investment that is needed to complete site renovations for the new stores is approximately RMB 6.1 million ($1.0 million). Management anticipates that the 11 stores will come together to generate approximately RMB 8.8 million ($1.4 million) in annual sales once they have reached a level of maturity, with a payback period of about four and a half years. China BCT is currently in process of obtaining all of the necessary licenses for the businesses and will be completely operational by the end of this year.
“The launch of these 11 self-opened stores will further strengthen our footprint in Guangxi by bringing the total number of ‘Baicaotang’ branded stores to 219,” commented Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT Pharmacy Group, Inc. “These stores will offer a full range of pharmaceutical products supported by excellent customer service. We remain focused on continuing the vertical integration of our growing retail network and our wholesale distribution and manufacturing businesses to become the leading retail pharmacy in Guangxi,” Mr. Tang added.
For more information on China BCT Pharmacy Inc and its new retail pharmacy stores, visit their website at www.china-bct.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The new retail stores are primarily located in Liuzhou City and Liucheng County and are, on average, a size of 67 square meters. The company has estimated that the total upfront capital investment that is needed to complete site renovations for the new stores is approximately RMB 6.1 million ($1.0 million). Management anticipates that the 11 stores will come together to generate approximately RMB 8.8 million ($1.4 million) in annual sales once they have reached a level of maturity, with a payback period of about four and a half years. China BCT is currently in process of obtaining all of the necessary licenses for the businesses and will be completely operational by the end of this year.
“The launch of these 11 self-opened stores will further strengthen our footprint in Guangxi by bringing the total number of ‘Baicaotang’ branded stores to 219,” commented Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT Pharmacy Group, Inc. “These stores will offer a full range of pharmaceutical products supported by excellent customer service. We remain focused on continuing the vertical integration of our growing retail network and our wholesale distribution and manufacturing businesses to become the leading retail pharmacy in Guangxi,” Mr. Tang added.
For more information on China BCT Pharmacy Inc and its new retail pharmacy stores, visit their website at www.china-bct.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)